70 likes | 177 Views
This study, published in The Lancet, presents a comprehensive analysis of the baseline characteristics of patients enrolled in the GISSI-HF trial. It details time to all-cause death and hospitalization for cardiovascular reasons using Kaplan-Meier curves. Additionally, it explores secondary outcomes, causes of death, and provides a predefined subgroup analysis of composite endpoints. The findings also address permanent treatment discontinuations and adverse drug reactions, shedding light on the efficacy and safety of treatment options for heart failure patients.
E N D
Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Baseline characteristics of patients GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Kaplan-Meier curves for time to all-cause death (A) and for time to all-cause death or admission to hospital for cardiovascular reasons (B) GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Secondary outcomes GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Causes of death GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Predefined subgroup analysis-composite endpoint of all-cause death or admission to hospital for cardiovascular reasons GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]
Permanent treatment discontinuations and adverse drug reactions GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]